Astrana Health (AMEH) Stock Forecast, Price Target & Predictions


OverviewOwnershipChartTranscripts

AMEH Stock Forecast


Astrana Health stock forecast is as follows: an average price target of $48.50 (represents a 22.26% upside from AMEH’s last price of $39.67) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

AMEH Price Target


The average price target for Astrana Health (AMEH) is $48.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $57.00 to $40.00. This represents a potential 22.26% upside from AMEH's last price of $39.67.

AMEH Analyst Ratings


Buy

According to 3 Wall Street analysts, Astrana Health's rating consensus is 'Buy'. The analyst rating breakdown for AMEH stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Astrana Health Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 19, 2022-Lake Street$40.00$29.4535.82%0.83%
Aug 08, 2022-Barclays$57.00$54.215.15%43.69%
Row per page
Go to

The latest Astrana Health stock forecast, released on Dec 19, 2022 by Lake Street company, set a price target of $40.00, which represents a 35.82% increase from the stock price at the time of the forecast ($29.45), and a 0.83% increase from AMEH last price ($39.67).

Astrana Health Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$39.67$39.67$39.67
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Astrana Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Astrana Health's last price of $39.67. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Dec 19, 2022Lake Street-BuyInitialise
Sep 21, 2022William Blair-OutperformInitialise
Aug 08, 2022BarclaysEqual-WeightEqual-WeightHold
Row per page
Go to

Astrana Health's last stock rating was published by Lake Street on Dec 19, 2022. The company Initialise its AMEH rating from "null" to "Buy".

Astrana Health Financial Forecast


Astrana Health Revenue Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Mar 21Mar 20Mar 19Jun 18
Revenue-----$335.62M$292.85M$261.70M$174.39M$163.90M$94.69M$122.23M
Avg Forecast$454.12M$424.94M$429.00M$346.37M$350.10M$201.42M$189.49M$183.11M$166.46M$60.04M$166.13M$175.29M
High Forecast$454.12M$424.94M$466.10M$352.30M$350.10M$241.70M$227.38M$219.73M$199.75M$72.05M$199.35M$210.34M
Low Forecast$454.12M$424.94M$391.90M$335.00M$350.10M$161.13M$151.59M$146.48M$133.17M$48.03M$132.90M$140.23M
# Analysts113421514198121010
Surprise %-----1.67%1.55%1.43%1.05%2.73%0.57%0.70%

Astrana Health's average Quarter revenue forecast for Sep 23 based on 2 analysts is $350.10M, with a low forecast of $350.10M, and a high forecast of $350.10M. AMEH's average Quarter revenue forecast represents a 4.31% increase compared to the company's last Quarter revenue of $335.62M (Mar 23).

Astrana Health EBITDA Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Mar 21Mar 20Mar 19Jun 18
# Analysts113421514198121010
EBITDA-----$33.36M$20.77M$32.68M$26.95M$12.46M$770.19K$14.42M
Avg Forecast$60.34M$56.47M$21.72M$46.03M$46.52M$19.75M$15.75M$17.95M$16.32M$10.14M$5.89M$11.98M
High Forecast$60.34M$56.47M$26.07M$46.81M$46.52M$23.70M$18.90M$21.54M$19.58M$12.17M$7.07M$14.38M
Low Forecast$60.34M$56.47M$17.38M$44.51M$46.52M$15.80M$12.60M$14.36M$13.06M$8.12M$4.72M$9.59M
Surprise %-----1.69%1.32%1.82%1.65%1.23%0.13%1.20%

2 analysts predict AMEH's average Quarter EBITDA for Sep 23 to be $46.52M, with a high of $46.52M and a low of $46.52M. This is 39.44% upper than Astrana Health's previous annual EBITDA (Mar 23) of $33.36M.

Astrana Health Net Income Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Mar 21Mar 20Mar 19Jun 18
# Analysts113421514198121010
Net Income-----$14.62M$471.00K$14.26M$13.15M$4.05M$-2.45M$7.87M
Avg Forecast$72.32M$63.00M$11.14M$7.98M$15.48M$10.13M$13.46M$9.21M$8.37M$3.04M$245.03K$3.46M
High Forecast$72.32M$63.00M$13.37M$9.38M$15.48M$12.15M$16.16M$11.05M$10.04M$3.65M$294.04K$4.16M
Low Forecast$72.32M$63.00M$8.91M$7.04M$15.48M$8.10M$10.77M$7.36M$6.70M$2.43M$196.03K$2.77M
Surprise %-----1.44%0.03%1.55%1.57%1.33%-10.00%2.27%

Astrana Health's average Quarter net income forecast for Sep 23 is $15.48M, with a range of $15.48M to $15.48M. AMEH's average Quarter net income forecast represents a 5.89% increase compared to the company's last Quarter net income of $14.62M (Mar 23).

Astrana Health SG&A Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Mar 21Mar 20Mar 19Jun 18
# Analysts113421514198121010
SG&A-----$21.18M$24.45M$11.94M$9.46M$11.83M$10.26M$11.47M
Avg Forecast$31.57M$29.54M$8.02M$24.08M$24.34M$7.29M$16.23M$6.62M$6.02M$8.88M$18.01M$14.91M
High Forecast$31.57M$29.54M$9.62M$24.49M$24.34M$8.74M$19.48M$7.95M$7.23M$10.65M$21.61M$17.90M
Low Forecast$31.57M$29.54M$6.41M$23.29M$24.34M$5.83M$12.99M$5.30M$4.82M$7.10M$14.41M$11.93M
Surprise %-----2.91%1.51%1.80%1.57%1.33%0.57%0.77%

Astrana Health's average Quarter SG&A projection for Sep 23 is $24.34M, based on 2 Wall Street analysts, with a range of $24.34M to $24.34M. The forecast indicates a 14.90% rise compared to AMEH last annual SG&A of $21.18M (Mar 23).

Astrana Health EPS Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Mar 23Dec 22Mar 22Mar 21Mar 20Mar 19Jun 18
# Analysts113421514198121010
EPS-----$0.31$0.01$0.32$0.31$0.08$-0.07$0.24
Avg Forecast$1.54$1.34$0.35$0.17$0.33$1.43$1.95$1.43$0.14$0.03$0.14$0.13
High Forecast$1.54$1.34$0.37$0.20$0.33$1.43$1.95$1.43$0.17$0.04$0.17$0.16
Low Forecast$1.54$1.34$0.32$0.15$0.33$1.43$1.95$1.43$0.11$0.02$0.11$0.10
Surprise %-----0.22%0.01%0.22%2.21%2.76%-0.51%1.85%

According to 2 Wall Street analysts, Astrana Health's projected average Quarter EPS for Sep 23 is $0.33, with a low estimate of $0.33 and a high estimate of $0.33. This represents a 6.45% increase compared to AMEH previous annual EPS of $0.31 (Mar 23).

Astrana Health Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
ACHCAcadia Healthcare Company$42.33$82.3394.50%Buy
HCSGHealthcare Services Group$11.17$17.3355.15%Hold
SGRYSurgery Partners$29.22$44.3351.71%Buy
AMEDAmedisys$95.39$143.3850.31%Hold
OPCHOption Care Health$22.49$32.7545.62%Buy
EHABEnhabit$7.63$10.2534.34%Hold
AMEHAstrana Health$40.82$48.5018.81%Buy
INNVInnovAge$5.90$6.8015.25%Hold
SEMSelect Medical$36.51$40.009.56%Buy
PNTGPennant Group$32.38$34.677.07%Buy
ADUSAddus HomeCare$128.96$129.400.34%Buy
UHSUniversal Health Services$208.83$208.47-0.17%Hold
EHCEncompass Health$100.23$97.00-3.22%Buy
ENSGEnsign Group$153.39$148.20-3.38%Buy

AMEH Forecast FAQ


Yes, according to 3 Wall Street analysts, Astrana Health (AMEH) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of AMEH's total ratings.

Astrana Health (AMEH) average price target is $48.5 with a range of $40 to $57, implying a 22.26% from its last price of $39.67. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for AMEH stock, the company can go up by 22.26% (from the last price of $39.67 to the average price target of $48.5), up by 43.69% based on the highest stock price target, and up by 0.83% based on the lowest stock price target.

AMEH's average twelve months analyst stock price target of $48.5 does not support the claim that Astrana Health can reach $60 in the near future.

AMEH's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $897.89M (high $944.1M, low $846.23M), average EBITDA is $112.3M (high $117.03M, low $106.83M), average net income is $33.59M (high $37.02M, low $30.62M), average SG&A $55.7M (high $57.57M, low $53.46M), and average EPS is $1.93 (high $1.96, low $1.91).

Based on Astrana Health's last annual report (Dec 2022), the company's revenue was $1.14B, beating the average analysts forecast of $372.59M by 205.43%. Apple's EBITDA was $133.35M, beating the average prediction of $33.71M by 295.62%. The company's net income was $49.05M, beating the average estimation of $22.67M by 116.36%. Apple's SG&A was $77.67M, beating the average forecast of $22.86M by 239.81%. Lastly, the company's EPS was $1.09, missing the average prediction of $3.38 by -67.78%. In terms of the last quarterly report (Mar 2023), Astrana Health's revenue was $335.62M, beating the average analysts' forecast of $201.42M by 66.63%. The company's EBITDA was $33.36M, beating the average prediction of $19.75M by 68.94%. Astrana Health's net income was $14.62M, beating the average estimation of $10.13M by 44.40%. The company's SG&A was $21.18M, beating the average forecast of $7.29M by 190.67%. Lastly, the company's EPS was $0.31, missing the average prediction of $1.43 by -78.31%